Travoprost Z ophthalmic solution with sofZia: clinical safety and efficacy

Travoprost Z (Travatan((R)) Z) ophthalmic solution has recently been approved for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. This new ophthalmic solution contains travoprost 0.004% as the active ingredient with sofZia (TM) as the preservative system consisting of zinc, borate, propylene glycol and sorbitol, and designed to be dissipated by the ocular tear film. Available clinical data have documented equal IOP-lowering safety and efficacy of travoprost Z when compared with travoprost preserved with benzalkonium chloride. This article discusses the current evidence on the clinical efficacy and safety of this recently released solution and expands on the potential benefits and future goals of newer preservative systems.